Gufic Biosciences appoints Rajesh Kaul as Senior President - Sparsh Cluster

With over three decades of vast experience in pharmaceutical industry, he has been instrumental in building robust brands across Critical Care, Corporate Hospitals, Government institutions and penetrated competitive markets with strategic finesse. He is skilled in scientific brand promotion and leadership development. Kaul has successfully led large‐scale operations and driven exponential business growth across India’s highly competitive healthcare landscape.

He has held senior leadership positions at several leading pharmaceutical companies, including Mankind Pharma Limited, Zydus Healthcare Limited, Aristo Pharmaceuticals, Alkem Laboratories Limited, Wockhardt Limited and Sun Pharmaceuticals Limited.

His responsibilities have spanned strategic P&L management for portfolios exceeding Rs 500 crore, along with oversight of over 400 professionals across sales, marketing, and business development functions. Kaul has a proven track record of scaling operations from ground zero to over Rs 300 crore, consistently achieving multi‐crore growth through effective market penetration, brand development, and operational excellence.

He has played a pivotal role in the launch of multiple high‐ impact brands such as Meroza, Germero, Aggramed, Swich, and Azetrohigh—each making a mark in the critical care segment. Renowned for his strategic foresight and executional strength, Kaul has transformed underperforming regions into profitable zones, successfully entered high‐value corporate hospital chains, and repeatedly surpassed performance targets. His core expertise includes scientific brand promotion, Key Opinion Leader (KOL) engagement, institutional and government business development, and high‐impact leadership and capability building.

Rajesh Kaul holds a Bachelor degree in Science and has done Management Program from Indian Institute of Management (IIM), Kozhikode and Finance Certification from Indian Institute of Management (IIM), Ahmedabad.